Medicine
F. Davatchi, H. Shams, Mozhgan Rezaipoor, B. Sadeghi‐Abdollahi, F. Shahram, A. Nadji, C. Chams‐Davatchi, Massoomeh Akhlaghi, T. Faezi, N. Naderi
tlooto Summary
The aim of this study was to evaluate the efficacy of rituximab in patients with ocular lesions, the main morbidity of Behcet's disease.
Abstract
Background: Ocular lesions, the main morbidity of Behcet’s disease (BD), are the most difficult to treat. The aim of this study was to evaluate the efficacy of rituximab.
Citation format
DAVATCHI, F., et al. Rituximab in intractable ocular lesions of behcet’s disease; randomized single‐blind control study (pilot study). International Journal of Rheumatic Diseases, 2010, 13.